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Conservation of the rapamycin-sensitive TOR signaling network among eukaryotes has been instru-
mental to the rapid progressmade in this field in recent years. A recent report inMolecular Cell (Urban
et al., 2007) now extends this conservation to include Sch9, an AGC protein kinase family member
from S. cerevisiae, which appears to be the long sought after yeast ortholog of mammalian S6 kinase
1 (S6K1) and a direct target for the rapamycin-sensitive TOR complex I.The TOR (target of rapamycin) signal-
ing network represents an important
mechanism by which cell growth is
coupled to extracellular cues, includ-
ing nutrient availability, in all eukaryotic
organisms examined to date (Wulls-
chleger et al., 2006). This network
was discovered through the action of
rapamycin, an immunosuppressant
and anticancer drug that inhibits the
activity of the large, evolutionarily
conserved TOR kinase, a member of
the PI3-like kinase family of serine/
threonine protein kinases. TOR as-
sembles with a number of other
proteins to form two distinct protein
complexes, termed TOR complex 1
and 2 (TORC1 and TORC2), of which
TORC1 is uniquely inhibited by rapa-
mycin. Present models suggest that
TORC1 and TORC2 independently
regulate distinct growth-related pro-
cesses—for example, ribosome bio-
genesis and cytoskeletal organization,
respectively—and thereby collaborate
to control both temporal as well as
spatial aspects of cell growth (Wulls-
chleger et al., 2006).
A unique interplay has existed over
the years with respect to results ob-
tained in the budding yeast S. cerevi-
siae and higher eukaryotic systems
and has proven crucial to our present
understanding of the architecture
of the TOR network. For example,
through the isolation of mutations
that confer dominant rapamycin resis-
tance, yeast genetics led to the initial
discovery of Tor1 and Tor2, the two
TOR homologs in yeast (Wullschleger
et al., 2006). Subsequent biochemical
approaches led to the identification of
a single mammalian ortholog, mTOR.The fact that yeast possesses two
TOR kinases and that Tor2, but not
Tor1, is essential allowed for detailed
genetic analyses that revealed that
Tor2 participates in a second essential
cellular activity that is not sensitive to
rapamycin (Wullschleger et al., 2006).
This Tor2-specific and rapamycin-
insensitive function was initially
chalked up to being an oddity of yeast
physiology. In retrospect, however,
this early discovery paved the way for
thinking about TOR as being involved
in multiple functions and presaged
the identification of distinct TORC1
and TORC2 complexes in both yeast
and mammals.
On the other hand, there has been
somewhat of a disconnect with re-
spect to the identity of target proteins
directly phosphorylated by TOR in
yeast versus mammals. Perhaps the
most well-known example involves
phosphorylation of S6 kinase 1 (S6K1)
by mammalian TORC1 (mTORC1).
S6K1 is a member of the AGC family
of protein kinases (named for their sim-
ilarity to protein kinases A, G, and C)
(Dann et al., 2007). Full activation of
S6K1 requires phosphorylation of sites
within a so-called hydrophobic motif
(HM) by mTORC1 as well as phosphor-
ylation within its activation loop by
phosphoinositide-dependent kinase 1
(PDK1) (see Figure 1). Activated S6K1
recognizes a number of downstream
targets, including ribosomal protein
S6 (RPS6) (hence its name). Many
years ago, phosphorylation of RPS6
was shown to correlate with trans-
lation of mRNAs that contain 50TOP
(terminal oligopyrimidine) structures,
including mRNAs that encode ribo-Cell Metabsomal proteins. In a scenario that
had become well entrenched in the
literature, it was hypothesized that
mTORC1 regulates ribosome biogen-
esis in mammalian cells at the level
of protein synthesis via activation of
S6K1, phosphorylation of RPS6, and,
ultimately, translation of 50TOP
mRNAs (Thomas and Hall, 1997). By
contrast, an analogous system did
not appear to operate in yeast (where,
for example, there are no 50TOP
mRNAs), and TORC1 has instead
been shown to regulate ribosome bio-
genesis at the level of transcription
(Wullschleger et al., 2006). Moreover,
no convincing homolog of S6K1 could
be identified in yeast. Now that the link
between S6K1 activation and 50TOP
translation has been thrown into
serious doubt (see Dann et al., 2007
and references therein), the question
has resurfaced as to whether an
mTORC1-S6K1 branch might be con-
served in yeast after all.
Enter Sch9, one of several AGC ki-
nases that have been identified in
yeast. Previous studies have demon-
strated that this protein is involved in
nutrient-dependent control of cell
growth and, moreover, that its phos-
phorylation state is responsive to rapa-
mycin treatment; however, its precise
connection to TOR signaling remained
unclear (Jorgensen et al., 2004). The
recent study by Loewith and co-
workers (Urban et al., 2007) signifi-
cantly extends these findings with the
demonstration that there are several
sites within the C-terminal region of
Sch9, including sites corresponding
to an HM motif, that are phosphory-
lated directly by TORC1 in vitro andolism 6, July 2007 ª2007 Elsevier Inc. 1
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See text for details.that these correspond to the major
rapamycin-sensitive phosphorylation
sites in vivo. By constructing mutant
forms of Sch9 that correspond to
hyper- or hypophosphorylated mimics,
the authors were able to attribute a
number of TORC1-specific readouts
(e.g., ribosome biogenesis and trans-
lational initiation) as being directly
influenced by Sch9. And yes, Sch9
was shown in this study to directly
phosphorylate RPS6. Finally, addi-
tional experiments revealed that there
is an independent phosphorylation
event within the activation loop of Sch9
by Pkh1, a yeast ortholog of PDK1. In
total, these experiments place Sch9
in a pathway that appears to be very
analogous to S6K1 (Figure 1).
This work by Urban et al. (2007) is
important in that it identifies what is
likely to be the first bona fide substrate
for TORC1 in yeast and will therefore
provide an important handle for dis-2 Cell Metabolism 6, July 2007 ª2007 Elsecting TORC1 function further in this
organism. However, this conclusion is
likely to generate some controversy,
as Sch9 has also garnered attention
as being the likely yeast ortholog of
mammalian PKB (also known as Akt),
an AGC kinase implicated in cell
growth regulation and cancer progres-
sion (Sobko, 2006). In mammalian
cells, PKB/Akt has long been impli-
cated in mTOR signaling; however, its
precise place within the pathway was
difficult to pinpoint. This confusion
has been largely resolved with the dis-
covery of two mTORCs and findings
by Sabatini and coworkers (Sarbassov
et al., 2005) that PKB/Akt is a direct
target for mTORC2. Thus, the model
that has emerged is that mTORC1
cooperates with PDK1 to activate
S6K1, whereas mTORC2 cooperates
with PDK1 to activate PKB/Akt (Dann
et al., 2007). A similar scenario can
now be established for yeast (Figure 1).sevier Inc.For example, Urban et al. have demon-
strated that Sch9 does not serve as
a substrate for TORC2, at least in vitro.
By contrast, a distinct AGC kinase,
Ypk2, has been shown to be a direct
target for TORC2, and this activation
step is required for actin polarization
and cell viability (Kamada et al.,
2005). Thus, activation of distinct
AGC kinases via direct phosphoryla-
tion by the two TORCs emerges as
a theme that is conserved in both yeast
and mammals.
Interestingly, both Tor1, which as-
sembles exclusively into TORC1, and
Sch9 have been identified recently as
influencing life span in response to
caloric restriction in yeast (Kaeberlein
et al., 2005). As pointed out by Urban
et al. (2007), it is possible that the
mTORC1-S6K1 cassette may also
turn out to play a role in life-span regu-
lation in higher eukaryotes. In other
words, the mammalian TOR field may
have some catching up to do of its
own.
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